Regulatory
Inside the Philippine FDA & ethics review timeline
What the streamlined submission pathway looks like in practice, and where local guidance saves weeks.
A Philippine clinical trial application clears two reviews before first-patient-in: the Philippine FDA and an accredited institutional ethics review committee. Exact review durations are pending a cited source (client-alignment item 2) — what follows is the structure of the pathway, not a promised timeline.
The two-track review
- Philippine FDA — reviews the clinical trial application itself: protocol, investigator's brochure, and manufacturing/import documentation for the investigational product.
- Ethics review committee — reviews the same protocol for participant safety and informed consent, run in parallel rather than strictly after FDA clearance.
Where local guidance saves weeks
Most delay in a first Philippine submission comes from formatting and documentation gaps against local requirements, not from the review itself taking longer than expected — a dossier prepared without local guidance typically comes back with clarification requests that a locally-informed submission avoids on the first pass.
What to prepare before submission
- A protocol and investigator's brochure already localized for Philippine FDA formatting requirements.
- Import documentation for the investigational product lined up ahead of the submission date, not started after.
- A named local regulatory contact who has taken a dossier through both reviews before.